Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;12(12):1961-1978.
doi: 10.1016/j.jchf.2024.05.014. Epub 2024 Jul 10.

Management of Iron Deficiency in Heart Failure: Practical Considerations and Implementation of Evidence-Based Iron Supplementation

Kazuhiko Kido  1 , Craig J Beavers  2 , Kenneth Dulnuan  3 , Nadia Fida  4 , Maya Guglin  5 , Onyedika J Ilonze  6 , Robert J Mentz  7 , Nikhil Narang  8 , Navin Rajagopalan  9 , Bhavadharini Ramu  10 , Yasar Sattar  11 , George Sokos  11 , Ewa A Jankowska  12
Affiliations
Free article
Review

Management of Iron Deficiency in Heart Failure: Practical Considerations and Implementation of Evidence-Based Iron Supplementation

Kazuhiko Kido et al. JACC Heart Fail. 2024 Dec.
Free article

Erratum in

  • Correction.
    [No authors listed] [No authors listed] JACC Heart Fail. 2024 Nov;12(11):1956-1960. doi: 10.1016/j.jchf.2024.09.002. JACC Heart Fail. 2024. PMID: 39505467 No abstract available.

Abstract

Iron deficiency (ID) is present in approximately 50% of patients with heart failure (HF) and even higher prevalence rate up to 80% in post-acute HF setting. The current guidelines for HF recommend intravenous (IV) iron replacement in HF with reduced or mildly reduced ejection fraction and ID based on clinical trials showing improvements in quality of life and exercise capacity, and an overall treatment benefit for recurrent HF hospitalization. However, several barriers cause challenges in implementing IV iron supplementation in practice due, in part, to clinician knowledge gaps and limited resource availability to protocolize routine utilization in appropriate patients. Thus, the current review will discuss practical considerations in ID treatment, implementation of evidence-based ID treatment to improve regional health disparities with toolkits, inclusion/exclusion criteria of IV iron supplementation, and clinical controversies in ID treatment, as well as gaps in evidence and questions to be answered.

Keywords: anemia; ferric carboxymaltose; heart failure; implementation; intravenous iron; iron; iron sucrose.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Narang has received honoraria from Boehringer Ingelheim, Abbott, and Zoll Medical. Dr Rajagopalan has served as a consultant for Abbott Laboratories. Dr Ramu has received an honorarium from Abbott. Dr Jankowska has received honoraria for lectures and/or participation in advisory boards from Vifor Pharma and Pharmacosmos. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.